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To investigate the mechanisms by which tumor-infiltrating 
lymphocytes exert their antitumor effects, tumor-specific 
tumor-infiltrating lymphocyte clones, as well as autologous 
tumor cell lines from primary and secondary tumors of two 
patients during the course of melanoma progression were 
established. Enrichment for tumor-infiltrating lymphocytes 
expressing CD25, as well as low concentrations of interleu-
kin-2 (30 IU Iml) in the culture medium, led to a preferential 
outgrowth of cells that express the high-affinity interleu-
kin-2 receptor. All of these expressed CD2, CD3, CDll, and 
CD25. Coculture of tumor-infiltrating lymphocyte clones 
with irradiated, autologous tumor cells induced an up to 
480% greater proliferative responses than recombinant in-
terleukin-2 alone. Approximately 60% of the tumor-infil-
trating lymphocyte clones showed cytotoxicity against the 
relevant tumor in a 4-h StCr-release assay. When tested in an 
T umor cells are known to express antigens that playa decisive role in the process of recognition and rejec-tion of tumors by the host immune system [1]. In human melanoma, a high degree of phenotypic het-erogeneity has been shown to exist not only among 
tumors derived from different patients, but also between autologous 
primary and metastatic lesions, among different metastases removed 
from the same patient, and even among clones isolated from the 
same cell line [2-5]. The accumulation of lymphocytes, predomi-
nantly T cells, at tumor sites may reflect an immunologic recogni-
tion of the neoplasm by the host, suggesting a specific function of 
tumor-infiltrating lymphocytes (TILs) directed against antigenic 
determinants present on tumor cells [6- 9] . The study of the nature 
of cells infiltrating the tumor may thus provide insight into the 
complex issue of tumor-host interactions. 
The mechanisms by which TILs exert their antitumor effects iI, 
vivo are unknown, although recent evidence suggests a correlation 
between the irl vitro property of autologous tumor lysis and therapeu-
tic response [10-14]. It has been shown that infused 1IlIn-labeled 
TILs traffic specifically to tumor deposits, and thus it is possible that 
TILs exert their effects via direct tumor contact and lysis [15]. Alter-
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18-h StCr-release assay, the number of tumor-infiltrating 
lymphocyte clones exhibiting cytotoxicity against the rele-
vant tumor increased to over 85%. In response to autologous 
tumor cells, nine of 15 clones secreted interferon-y, tumor 
necrosis factor-a, or both. Cytokine production was not re-
stricted to either CD4+ or CD8+ T cells because both CD4+ 
and CD8+ tumor-infiltrating lymphocyte clones secreted cy-
tokines. Tumor-infiltrating lymphocyte tumor interaction 
appears to be lesion specific because induction of prolifera-
tion and cytokine production, as well as susceptibility to cy-
tolysis, was found not only restricted to the autologous sys-
tem, but also to the specific lesion. The pattern of 
tumor-infiltrating lymphocyte tumor interaction specificity 
indicates a possible loss of antigens expressed on the tumor 
during disease progression. ] Invest Dermatol 101: 15 - 21 J 
1993 
natively, TILs may initiate factors that destroy tumor cells or that 
recruit other elements of the immune system for this task. It has 
been shown that interleukin-2 (IL-2) -activated TILs produce 
mRNA for various cytokines, including granulocyte-macrophage 
colony-stimulating factor, tumor necrosis factor (TNF)-a, and 
TNF-P [16]. Although many studies documenting cytokine release 
by T lym,Phocytes stimulated wit~l polyclonal activators have been 
reported l17 -19], only a few studtes addressed the specific response 
of human T cells to tumor by this mechanism [20,21]. 
In melanoma, it is possible to obtain effectors both reactive 
against a large target cell repertoire, and therefore unrestricted by 
products of the major histocompatibility complex, and that recog-
nize and kill the autologous neoplastic cells in a major histocompati-
bility complex-restricted fashion [9-14,22,23J. Because many of 
the T cells infiltrating tumors may not necessarily be involved in 
anti-tumor effector functions, it is important to establish a func-
tional role for the T cells under investigation. The technology of 
cloning functional T-cell subsets il1l1itro has proved to be a powerful 
tool in studies of cellular immune response to cell-surface-
associated antigens [4,24 - 29]. Selection of T cells expressing the 
high-affinity IL-2 receptor for cloning, as well as using cloning 
conditions with low concentrations of IL-2, has been suggested to 
give a greater yield of tumor-specific T -cell clones than the standard 
cloning protocol [30]. 
The objectives of our study were 1) to develop autologous tumor-
specific T -cell clones from the TILs of primary and secondary mela-
noma; 2) to investigate the specificity of T-cell response against 
autologous tumor cell lines; and 3) to investigate the mechanisms 
used by these T cells during T -cell- tumor interaction. We report 
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Table I. C haracteristics of Tumor Lesions and Yield of TILs 
Tumor Total of Cel ls 
T umor Weight Obtained TILs 
Patient and Site (g)' (X 10- 6) (%)6 
B Primary, face, 1.2 33 29 
Breslow 1.5 mm 
Secondary,' skin 1.6 29 31 
S Primary, arm, 0.9 26 34 
Breslow 3.0 mm 
Secondary / regional 5 123 44 
lymph node' 
• O nl y parts of the tumor were used for generation ofTILs. 
• As percent of the total of cells yielded. 
, Secondary tumor occurred 9 months after the primary tumor at a distant site. 
J Secondary tumor was present when primary tumor was diagnosed. 
, Tumor tissue was segregated frolll unaffected lymphatic tissue insofar as macroscop-
icall y possible. 
here that stable, autologous tumor-specific T-cell clones can be 
derived from TILs of primary and secondary melanoma using a 
cloning protocol that favors the growth of T cells expressing the 
high-affinity IL-2 receptor. The majority of these clones were capa-
ble of mediating a specific response to the relevant tumor-inducing 
proliferation, cytotoxici ty, and interferon-y (IFN-y) and TNF-a 
production by them. 
MATERIALS AND METHODS 
Melanoma Cell Lines [31] Dispersed cells were obtained by 
grating tumor fragments from freshly resected melanomas against a 
0.3 X 0.3-mm metallic mesh immersed in complete medium con-
sisting of RPM I 1640 supplemented with 10% fetal bovine serum 
(FBS) , 1 % penicillin, 1 % streptomycin, 1 % glutamine, and 1 % 
sod ium pyruvate. A portion of these cells was frozen for later use in 
T-cell stimul ation and cytotoxicity assays. The remaining cells were 
plated into six-well collagen-coated culture plates at 2000 cells/ 
well in complete mediuin and grown in humidified incubators at 
37 °C with 5% CO2 , Fibroblast contamination was suppressed by 
addi ng geneticin (250 ,ug/ml) (Gibco BRL, Berlin, Germany) . Dur-
ing the initial 3 weeks of growth, 25% of the spent medium was 
removed and replaced three times a week. Tumor lines were main-
tained as monolayers and passaged by trypsinization with 0.0625% 
trypsin plus ethyl ~n ediamin~tetraacetic acid as required . Character-
istics of tumor leSIOns and yIeld of cells are gIven 111 Table I. 
Preparation ofTILs [32] Tumor cell suspensions were prepared 
by mincing freshly resected tumors into small pieces that were di-
gested for 12 h in RPMI 1640 medium supplemented with 5% FBS, 
1 % penicillin/streptomyc1l1, 1 % glutam1l1e, and 1 % sodIUm pyru-
vate containing 0.1 % collagenase type IV (200 U / g) and 0.005% 
deoxyribonuclease type I (100 U/mg) (Sigma Chemicals Co., St. 
Louis, MO) and then passed through a steel sieve. After washing 
rwice with Hanks' balanced salt solution, viable cells were separated 
on a Ficoll/Hypaque gradient at 600 X g for 20 min, washed rwice, 
counted, and placed into six-well tissue culture plates 111 complete 
medium at a concentration of 5 X 105 cells/ml. Complete medium 
was supplemented with IL-2 (30 IU/ml) (Eurocetus, Amsterdam, 
The N etherlands). C haracteristics of tumor lesions and yield of 
TILs are given in Table I. 
Immunomagnetic Isolation of CD25+ Cells The indirect im-
munomagnetic isolation of CD25+ cells has been described in detail 
elsewhere [33] . Briefly, the TILs were suspended in complete me-
dium at a concentration of 108 cells/ml. Thereafter, 0 .1 mg CD25 
monoclonal antibody (MoAb)/106 TILs were added, and the cells 
were incubated for 1 h at 4 ° C. The cells were washed twice in 
Hanks' balanced salt solution, resuspended in complete medium, 
and incubated with sheep anti-mouse immunoglobulin-G (I gG) -
coated Dynabeads M-450 (Dynal, Oslo, Norway) (7.5 X 105 
beads/ l06 peripheral blood mononuclear cells) for 30 min with 
gentle rotation. Cells attached to Dynabeads were recovered with 
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the MPC-6 magnet (Dynal) and washed three times in complete 
medium. T he cell/bead suspension was incubated for 24 h at 37"C, 
resulting in detachment of most of the beads from the cells. Thereaf-
ter, the cells were separated from the beads using the MPC-6 mag-
net. T he efficiency of cell separation was confirmed by flow cytome-
try (less than 5% contaminating cells). 
Generation of Cloned Human TIL lines TIL clones were ob-
tained using a limiting dilution technique [24] by plating 0.5 cells/ 
well onto a feeder layer of 5000 autologous, irradiated (50 Gray) 
melanoma cells-obtained from the same tumor specimen-and 
5000 irradiated (50 Gray) cells of the Epstein-Barr virus-
transformed B-cellline LAZ 509 per wel l. Only CD25+ TILs were 
used for cloning. Colonies were expanded by addition of culture 
medium containing recombinant IL-2 (rIL-2) (30 IU /ml) every 3 d. 
The culture medium consisted of RPMI 1640 suppl emented with 
20% human AB serum, 1 % penicillin/streptomycin, 1 % glutamine, 
and 1 % sodium pyruvate. All cell lines used in this study were 
subcloned at least three times at 1000 cells/well. The phenotypes of 
TIL lines used in this study are summarized in Table II. TIL lines 
were designated pT if derived from a primary tumor and sT if 
derived from a secondary tumor. T he use of the limiting dilution 
technique for cloning is widely accepted as a standard protocol to 
obtain clonal cell lines, but each clone has to be suspected of being 
polyclonal [34]. 
Human Leukocyte Antigen Phenotyping Peripheral blood 
lymphocytes were collected from 20 ml of heparinized blood by 
density gradient centrifugation, washed w ith RPMI/Tris(hydroxy-
methyl)aminomethane (Tris) (RPMI 1640 and Tris buffer 60 mM, 
pH 7.45, 1 + 1), and resuspended in 2 ml of RPMI/Tris supple-
mented with 5% FBS. A 2-ml plastic syringe filled with 0.14 g 
nylon wool (Baxter Deutschland GmbH, Unterschleissheim, Ger-
many) was rinsed with RPMI/Tris/FBS 5% and incubated for 30 
min at 37"C. The nylon wool column was overlaid with the cell 
suspension , and the syringe was sealed with parafilm and incubated 
for 45 min at 37°C. Afterward, T cells were rinsed into a plastic tube 
by adding 10 ml of phosphate-buffered saline, and B cells were 
squeezed from the syringe using 20 ml ofRPMI/Tris/FBS 10%. B 
and T cells were washed separately three times and adjusted to 2000 
cells/,ul. The standard complement-dependent microlymphocyto-
toxicity test (Biotest Diagnostic, Munich, Germany) was carried out 
in microtiter trays with incubation times of 30 and 60 min for 
human leukocyte antigen (HLA) class I and 60 and 120 min for class 
II typing, respectively. The HLA phenotype of patient B was Al , 
A3, B7, B8, Cw7, DR2, DR3 and that of patient S was A2 A28, 
Bw53, Cw6, DRw13. 
MoAbs MoAbs used in this study have been previously described 
in detail and are commercially available (Becton Dickinson, San 
Jose, CA; T Cell Science, Cambridge, MD) . 
Phenotypic Analysis by Flow Cytometry Cells were washed 
twice with phosphate-buffered saline and then incubated with puri-
fied human IgG for 10 min to inhibit subsequent MoAb binding to 
Fc receptors. After washing as before, 106 cells were incubated for 
30 min with the primary MoAbs. Following two washes with 
Hanks' balanced salt solution containing 0.2% sodium azide, cells 
were stained for 30 min with Fab~ goat anti-mouse IgG fluorescein 
isothiocyanate conjugate. After washing as before, the cells were 
incubated for 20 min with excess mouse IgG to block free goat 
anti-mouse IgG-binding sites. The goat anti-mouse IgG and block-
ing steps were omitted for samples stained with directly fluorescein 
isothiocyanate-conju gated MoAbs . After the blocking step, phy-
coerythrin-conjugated MoAb was added for 30 min, followed by 
two additional was hes. All incubations and washes were performed 
at 40 °C. Cells were analyzed with a FACScan (Becton Dickinson, 
San Jose, CAl (488 or 590 nm for fluorescein isothiocyanate and 
phycoerythrin, respectively). The noise threshold was set to exclude 
volume signals below those of lymphocytes. All analyses were per-
formed using photomultiplier voltages and gain settings that were 
standardized by fluorescent calibration beads. All signals were pro-
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Table II. Characterization of TIL Clones 
Proliferative Response' Against 
Phenotypeb Autologous, Autologous, Heterologous Cytotoxid Primary Tumor Secondary Tumor Tumor Line Against 
Clone and Origin' CO2 CD3 CD4 CD8 COli CD25 (epm X 10- 3) (cpm X 10- 3) (cpm X 10- 3) , Autologous Tumor 
+ + + 21.5 ± 4.8 4.9 ± 0.6 3.9 ± 0.5 + 
+ + + 18.0 ± 4.1 4.2 ± 0.7 4.1 ± 0.6 
+ + + 19.5 ± 3.9 3.9 ± 0.6 3.7 ± 0.5 + 
+ + + 16.4 ± 3.1 17.2 ± 2.9 4.1 ± 0.6 
pTE 1 + + 
pTB 3 + + 
pTB 5 + + 
sTB 2, skin + + 
sTB 3, skin + + + + + 17.0 ± 4.2 18.4 ± 3.4 4.4 ± 0.5 + 
sTB 5, skin + + + + + 14.0 ± 3.4 16.7 ± 2.8 3.8 ± 1.0 
sTB 6, skin + + + + + 14.4 ± 3.2 17.0 ± 3.0 4.2 ± 0.6 + 
+ + + 24.6 ± 3.6 4.8 ± 0.8 3.9 ± 0.7 
+ + + 22.0 ± 3.1 3.8 ± 0.6 3.5 ± 0.5 + 
+ + + 23.3 ± 2.9 4.4 ± 0.7 4.0 ± 0.6 + 
+ + + 22.6 ± 3.0 4.2 ± 0.6 3.1±1.0 
pTS 2 + + 
pTS 4 + + 
pTS 7 + + 
pTS 8 + + 
sTS 3, lymph node + + + + + 21.4 ± 2.1 22.8 ± 3.5 3.6 ± 0.6 + 
sTS 4, lymph node + + + + + 19.2 ± 3.2 20.3 ± 2.6 4.2 ± 0.5 
sTS 6, lymph node + + + + + 18.4 ± 2.8 19.8 ± 3.4 5. 1 ± 0.9 + 
sTS 7, lymph node + + + + + 20.4 ± 3.1 21.1 ± 2.8 3.9 ± 0.5 + 
• pT, primary tumor; sT, secondary tumor; B, patient B; S, patient S; HLA phenorype of patientB was AI . A3. B7. B8, Cw7, DR2. DR3 and that ofpatientS was A2 A28, Bw53, 
Cw6, DRwI3. 
• Phenotype of clones was determined by flow cytometry. 
, Proliferation was determined as described in Materials alld Methods; results arc given as average ± SD of three experiments. 
J Cytotoxicity was tested against autologous, lesion-specific rumor cells in a standard 4-h" Cr-release assay . 
• As allogenic melanoma lines. lines from patient B were used for TIL clones from patient S and vice versa. 
cessed using a logarithmic amplification. Irrelevant fluorescein 
isothiocyanate-conjugated mouse IgG2a MoAb controls were used 
to assess the degree of non-specific antibody binding to each cell 
preparation and to allow for the establishment of markers for distin-
guishing positive and negative cell populations. 
Proliferation Assay The proliferative response was measured by 
culturing 5 X 104 cells/well for 2 d in flat-bottomed microtiter 
plates. Proliferation was quantified by 3H-thymidine uptake in trip-
licate, as previously described [30] . 
Cytotoxicity Assay Cell-mediated lysis was measured in stan-
dard 4- and 18-h SICr-release assays, as briefly described below [19] . 
U-bottomed plates were used for cytotoxiciry assays in conjunction 
with RPMI 1640 supplemented with 10% FBS. Assays were per-
formed at various effector/target ratios using 5 X 103 slCr-labeled 
target cells/well. Plates were incubated for 4 or 18 h, and a 70-JlI 
aliquot was then removed from each well , and the specific slCr_ 
release was measured. Results are expressed as follows: 
% Cytotoxiciry = 
Experimental release (cpm) - Spontaneous release (cpm) 
Maximum release (cpm) - Spontaneous release (cpm) , 
where spontaneous release was assessed by incubating target cells in 
the absence of effector cells, and maximum release w as determined 
in the presence of 1 % Triton X-I00. 
TNF-a and IFN-y Enzyme-Linked Immunosorbent Assay 
TNF-a and IFN-y concentrations were measured in cell-free super-
natants by enzyme-linked immunosorbent assay (Endogen, Boston, 
MA) , as previously described [24] . 
RNA Isolation and Northern Blot Analysis At different time 
periods following coculture of TIL clone pTB5 with the autologous 
tumor cell line pMB, pTB5 and pMB cells were separated, and total 
RNA of pTB5 cells was prepared by ultracentrifugation over a CsCI 
cushion. Then 10 Jlg RNA/lane was size fractionated on a formal-
dehyde containing 1 % agarose denaturating gel and transferred to a 
nylon membrane (Amersham Hybond, Braunschweig, Germany). 
The probes were labeled using the random hexanucleotide priming 
technique. Hybridizations were carried out with 2.5 X 106 cpm/ml 
of hybridization solution [50% formamide, 5 X saline sodium 
phosphate ethylellediaminetetraacetic acid, 5 X Denhardt's solu-
tion, 0.1 % sodium dodecyl sulfate, and 100 Jlg/ml calf thymus 
DNA] at 42 °C for 18 h. Filters were washed twice in 2 X saline 
sodium phosphate ethylenediaminetetraacetic acid, 0.1 % sodium 
dodecyl sulfate at room temperature for 15 min and twice in 0.1 X 
saline sodium phosphate ethylenediaminetetraacetic acid, 0 .1 % so-
dium dodecyl sulfate at 65 ° C for 30 min. Filters were exposed on 
Kodak XAR-5 film for autoradiography [24]. 
eDNA Probes IFN-y cDNA was a gift fro m Dr. Heinze (DRK 
Blutspendedienst, Springe, Germany). The T NF-a cDNA was 
kindly provided by Knoll AG (Ludwigshafen, Germany) . 
Statistical Analysis The student paired t test was used to deter-
mine the significance of differences between two groups. A result 
was considered significant if p < 0.01. 
RESULTS 
Generation of TIL Clones TIL clones were generated using a 
limiting dilution technique with low concentrations of IL-2 (30 
IU /ml) . Selection of TILs expressing the p55 a-chain of the inter-
leukin-2 receptor (IL-2R) for cloning increased the cloning fre-
quency from 0.8 to 3.2 clones/96 wells. 
The TIL clones were tes ted for cell-surface marker expression 
using MoAbs against T-cell subsets. The results for the clones used 
in this study are summarized in T able II. All clones expressed CD2, 
CD3, CD11, and CD25. Approximately 33% of clones reacted 
with anti-CD4 MoAb and 66% w ith anti-CD8 MoAb. No correla-
tion between the expression of CD4 or CD8 and the origin of the 
TIL clones from a primary or secondary tumor could be fou nd . In 
addition, testing for MoAb reactiviry directed against antigens 
mainly expressed on natural kil ler cells was perfo rmed. As expected, 
a number of clones showed a low reactiviry with anti-CD56 MoAb 
(40%), whereas none of the clones showed a high reactiviry with 
this MoAb (data not shown). Because CD56 is not a specific marker 
for natural killer cells in long-term cultures, we also used CD16 
MoAb, which is thought to be more specific. N one of the clones 
showed CD16 expression. 
Proliferation of TIL clones was tested in response to irradiated (50 
Gray) melanoma cell lines and low concentrations of rIL-2 (30 
IU /ml) after a 48-h culture in complete medium without further 
stimulation. Under these conditions, rIL-2 alone (data not show n) 
or co-culture with heterogeneous melanoma cells was not sufficient 
to induce a good proliferative response (Table II) . Coculture of T IL 
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clones with autologous, lesion-specific tumor lines and rIL-2 in-
duced up to 460% greater proliferative response compared with 
rIL-2 alone. Melanoma cell lines derived from primary tumors were 
able to induce an enhanced proliferation of TIL clones in a non-
lesion-specific way such that both TILs from primary and secondary 
tumors were activated . In contrast, melanoma lines from secondary 
tumors did not change the proliferative response of TIL clones from 
primary tumors. 
Cytotoxic Activity of TIL Clones The TIL clones obtained 
under the conditions described above showed little or no natural 
killer act ivity as measured by the killing ofK562 (less than 10% lysis 
in an effector/target ratio of 40: 1, data not shown). Lymphokine-
activated killer cell activity as determined by the ki lling of Daudi 
ce lls ranged between 17% and 25% in an effector/target ratio of 
40: 1 in a 4-h SICr-release assay for the following clones: pTB1, 
pTB5, sTB3, sTB6, pTS4, pTS7, sTS6, and sTS7 (data not shown). 
Table II documents the lytic activity of TIL clones against the 
autologous, lesion-specific tumor cell line. Sixty percent of TIL 
clones mediated cytotoxicity against the corresponding tumor cell 
lines, with up to 35% of specific lysis in a 4-h assay. The cytolytic 
activity was not w holly restricted to CD8+ clones because sTS3 (a 
CD4+ clone) efficiently killed the autologous tumor cell line sMS. 
A number of TIL clones generated from metastatic tumors were able 
to lyse melanoma lines from primary tumors (sTB3, sTB6, sTS3, 
sTS6, sTS7), whereas none of the clones from primary tumors were 
able to kill tumor lines from metastatic tumors (Fig 1). 
TIL clones pTB3, sTB2, pTS8, and sTS4, which showed no 
specific lysis in the standard 4-h 51Cr-release assay against the auto-
logous tumor lines, were effective in killing those lines in an 18-h 
assay (Fig 2). 
Specific Cytokine Production of TIL Clones in Response to 
Autologous Tumor Cell Lines To assess cytokine production 
by T IL clones, stimulation with autologous, lesion-specific mela-
noma lines was performed. Cytokine production by the tumor cells 
was excluded by separation of TIL clones from tumor lines after a 
6-h co-culture. IFN -y and TNF-a concentrations were measured in 
cell-free supernatants after a 24-h culture. Nine of 15 clones se-
creted increased amounts of IFN-y, T N F-a, or both cytokines 
(seven of 15 clones) in response to the relevant tumor (Table III). 
Although most T IL clones secreted small amounts of IFN-y (aver-
age 105 U/ml) and TNF-a (average 219 pg/ml) cO~lstitutively , 
secretion was significantly enhanced by stimulation With the rele-
vant tumor cell line (maximum 331 U/ ml and 937 pg/ml; p < 
0.01) (Table III) in these TIL clones. For allogeneic tumor lines-
or tumor lines generated from secondary tumors when TIL clones 
obtained from primary tumors were used - no major changes in the 
secretion ofIFN-y and TNF-a were observed. However, melanoma 
lines from primary tumors were able to stimulate cytokine produ~­
tion in autologous TIL clones generated from metastases (maxI-
mum 310 U/ml and 886 pg/ml; p < 0.01). Hybridization of 
poly(A)-enriched RNA from TIL clone pTB5 obtained immedi-
ately, 2, 4, 12, and 24 h following coculture with the irradiated 
autologous tumor line pMB using cDNA probes for IFN-y and 
TNF-a revealed that peak mRNA accumulation for IFN-y oc-
curred after 4 h and for TNF-a after 12 h (Fig 3). To exclude the 
possibility that mRNA accumulation for IFN-y and TNF-a oc-
curred in the tumor cells themselves, pTB5 was separated fro m 
pMB prior to RNA isolation. 
DISCUSSION 
In this study, tumor-specific TIL clones were isolated from primary 
and secondary melanomas from two patients during their course of 
disease progression. C lones were isolated under culture conditions 
that preferentially allowed the outgrowth of cells that express the 
high-affinity IL-2R. This aim was achieved by enrichment ofTILs 
expressing CD25 and low concentrations of IL-2 in the culture 
medium. This approach was chosen because expression of the high-
affinity IL-2R on T cells may be a sign of their involvement in 
anti-tumor functions [8,30]. Antigenic challenge of the T-cell re-
ceptor mediates tanscriptional activation of both the IL-2 as well as 
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Figure 1. Cytotoxicity of T IL clones against autologous tumor cell lines . 
TIL clones pTBl, pTBS, sTB3, sTB6, pTS4, pTS7, sT S3 , and sTS7 were 
tested for cytotoxicity against autologous tumor cell lines derived from 
primaty (squares) or secondaty (circles) tumors and heterologous tumor lines 
from primary tumors (triallgles). Cell -mediated lys is was meas ured in a stan-
dard 4-h 5lCr-release assay, as described ill Materials alld Methods, using 
different effector/target ratios ranging from 1 : 10 to 1 : 40. Results are ex-
pressed as average ± SD of three experiments. 
the IL-2R genes. This makes T cells competent to receive cell cycle 
progression signals that lead to clonal expansion of the antigen-spe-
cific cells [35-38]. 
TIL clones obtained under these conditions were tes ted in anti-
gen-dependent proliferation assays, as proposed by Degiovanni et III 
[4] . W e confirmed their findin gs, showing that tumor-specific T-
cell clones can be reactivated to proliferation with small numbers of 
relevant melanoma cells. Phenotypic analysis showed that these 
TIL clones exclusively express T-cell markers with a CD4/CD8 
ratio of 0.5. Approximately 60% of the TIL clones showed cytotox-
icity against the relevant tumor in a 4-h StCr-release assay. No 
efficient killing of heterologous tumor cells was detected. When 
tested in an 18-h 51Cr-release assay, the number of TIL clones that 
were cytotoxic against the relevant tumor increased to over 85%. 
Measurement of IFN-y and TNF-a in culture supernatants of TIL 
clones following stimulation with the relevant tumor revealed that 
nine of 15 clones secreted increased amounts ofIFN-)', TNF-a, or 
both cytokines in response to tumor cel ls. These findings could be 
confirmed by detecting an accumulation of mRNA for these cyto-
kines in TIL clones after stimulation with rel evant tumor cells. This 
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Figure 2. TIL clones that showed no specific lysis in the standard 4-h 
51Cr-release assay against the autologous lesion-specific tumor lines were 
effective in killing those lines in an 18-h assay. Cytolysis was measured in a 
standard 18-h s'Cr-relcasc assay, as described in Materials and Methods, using 
a.n effector/target ratio of 1 : 40. Results arc expressed as average ± SO of 
three experiments. 
observation corroborates the recent reports of Barth et al [20J and 
Schwartzentruber et 01 [21] who demonstrated the specific release of 
proinflammatory cytokines by TILs in bulk cultures in response to 
autologous tumor cells . We were able for the first time to reproduce 
their findings on a clonal level. In addition, we clearly demonstrated 
that cytokine production is not restricted to either CD4+ or CD8+ T 
cells because both CD4+ and CD8+ TIL clones secreted these cyto-
kines. Because both IFN-y and TNF-a have direct tumoricidal activ-
ities against melanoma cells, coupled with all TIL clones secreting 
these cytokines showing cytotoxicity against the relevant tumor (in 
either the 4-h- or the 18-h 51Cr-re1ease assay), it is proposed that the 
cytokine production in specific response to the tumor is one of the 
mechanisms by which TILs exert their tumoricidal activity. 
For melanoma, a high degree of phenotypic heterogeneity exists. 
This has been shown 1) among tumors derived from different 
patients', 2) between autologous primary and metastatic lesions; 
3) among different metastases removed from the same patient; and 
4) among clones isolated from the same cell lines [2 - 5] . Guerry and 
co-workers have previously shown that cell lines cultured from 
lesions early in the pathway of melanocytic tumor progression (i.e., 
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radial growth phase) stimulate autologous T-cell proliferation ill 
Il irro by presentation of soluble tetanus toxoid, whereas cell lines 
derived from late me1anocytic lesions (i .e., vertical growth rhase of 
primary melanoma) do not [39]. In addition, a variety 0 studies 
have demonstrated the heterogenous susceptibility of melanoma 
clones to lysis by autologous cytotoxic T lymphocytes [2,11,27,40]. 
Susceptibility to lysis by autologous cytotoxic T lymphocytes has 
not been directly correlated with the presence or absence of any 
particular surface antigen; nevertheless, it has been postulated that 
differential antigen expression may facilitate the escape of tumor 
sub populations from immunologic recognition [1 ,40] . 
Although this study concentrated on the effector functions of 
TIL clones, and we only investigated a low number of tumor lesions 
from the same patients, it is obvious that the melanoma cell lines 
show some heterogeneity in their ability to stimulate proliferation 
and cytokine production in TIL clones, as well as in their susceptibil-
ity to cytolysis. If TIL clones were co-cultured with autologous, but 
not lesion-specific tumor cells, melanoma lines from primary 
tumors were sufficient to induce a strong proliferative response, as 
well as IFN-y and TNF-a production in TIL clones from secondary 
melanoma. In contrast, melanoma lines obtained from metastatic 
tumors were unable to induce a proliferative response or cytokine 
production greater than that induced by rIL-2 alone in TIL clones 
derived from the autologous primary. TIL clones generated from 
metastatic tumors were able to lyse melanoma lines from primary 
and metastatic tumors, w hereas none of the clones from primary 
tumors were able to kill tumor lines from metastatic tumors. Our 
findings confirm previous reports and additionally point out the 
complexity of host anti-tumor immunoresponse and tumor-escape 
mechanisms because the immune system seems to be able to react 
against tumor cells that escaped from the first-line anti-tumor im-
mune response ;11 vivo . The mechanisms by which tnelanomas may 
escape immunosurveillance are not yet clear but may involve shed-
ding of membrane molecules, such as intercellular adhesion mole-
cule-I, the loss of major histocompatibility complex molecules, or 
defects in antigen presentation [40- 44]. 
In summary, it was demonstrated in this study that stable autolo-
gous tumor-specific T-cell clones can be derived from TILs of pri-
mary and secondary melanomas using a cloning protocol that favors 
the growth ofT cells expressing the high-affinity IL-2R. The ma-
jority of these clones were capable of mediating a specific response 
to the relevant tumor, inducing proliferation, cytotoxicity, and 
IFN-y and TNF-a production by them. This confirmed recent re-
ports concerning cytokine production of bulk-cultured TILs in re-
sponse to autologous tumor for the first time on a c!onallevel. This 
approach enabled us to further specify the characteristics of those 
Table Ill. Cytokine Production of TIL Clones in Response to Tumor Cell Lines' 
IFN-y (10-2 V/ml) TNF-a (10-2 pg/ml) 
Autologous, Autologous, Heterologous Autologous, Autologous, Heterologous 
Primary Secondary Tumor Line Primary Secondary Tumor Line 
Clone" None Tumor (mm) Tumor (mm) (mm) None Tumor (mm) Tumor (mm) (mm) 
pTE 1 NO NO NO 0.88 NO NO NO NO 
pTB 3 1.22 2.77 1.30 1.08 2.03 9.21 2.19 2.14 
pTB 5 1.45 2.83 1.37 1.33 2.48 8.89 2.52 2.43 
sTE 2 1.53 2.47 3.03 1.31 2.57 8.02 9.28 2.78 
5TB 3 0.79 0.85 0.91 0.84 1.88 2.35 2.37 2.01 
5TB 5 0.81 0.88 0.85 0.93 2.04 2.63 2.88 2.11 
5TE 6 1.11 3.10 3.23 1.20 2.59 6.93 8.44 2.61 
pTS 2 NO NO NO ND ND NO NO 1.86 
pTS 4 1.20 3.09 0.96 1.16 2.21 9.31 3.02 2.17 
pTS 7 0.83 0.84 0.92 0.86 1.69 1.99 1.85 1.62 
pTS 8 0.98 2.97 1.04 0.87 2.72 2.84 2.63 2.69 
sTS 3 1.35 2.76 3.31 1.13 2.19 7.73 9.37 2.30 
sTS 4 0.86 0.71 0.90 0.93 2.06 8.86 7.38 2.04 
5TS 6 NO ND NO NO ND NO NO NO 
sTS 7 1.23 2.99 3.17 1.16 2.63 7.27 8.74 2.50 
• Cywkine production was measured in specific enzyme-linked immullosorbent assays, as described in Materials alld Methods; remIts arc given as average of three experiments. 
so did not exceed 10%. NO, not detectable. 
I Abbreviations as in Table II. 
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Figure 3. Kinetics of accumulation of IFN-)' and TNF-a mRNA in TIL 
clone pTB5 in response to autologous tumor cells. Hybridization of 
poly(A)-enriched RNA from 2 X 107 cells of TIL clone pTBS obtained 
immediately, 2, 4, 12, and 24 h after start of the coculture with the irra-
diated, autologous tumor line pMB. Assays using eDNA probes for IFN-y 
(A) and TNF-a (B) were performed as described in Materials and Methods. 
pTB5 was separated from pMB prior to RNA isolation. 
cytokine-producing cells. The selection of IL-2R - expressing cells 
for cloning seems to increase the fidelity of generating tumor-speci-
fic T-cell clones. On the basis of this concept, activation and expan-
sion protocols can be modified, enabling more efficient generation 
of cytotoxic lymphocytes for anti-tumor immunotherapy . 
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